Craft

Takeda

Stock Price

¥4.1 K

2024-04-17

Market Capitalization

¥6.4 T

2024-04-17

Revenue

¥4 T

FY, 2023

Takeda Summary

Company Summary

Overview
Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. It focuses on five business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies Immunology, Oncology, and Neuroscience. The company offers treatments for complex perianal fistulas, acid-related diseases, cell lung cancer, and hormone-responsive cancers, as well as enzyme replacement therapy, inhibitors, and other products.
Type
Public
Status
Active
Founded
1781
HQ
Tokyo, JP | view all locations
Website
https://www.takeda.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Christophe Weber

    Christophe Weber, Representative Director, President & CEO

  • Costa Saroukos

    Costa Saroukos, Director, Chief Financial Officer

  • Mwana Lugogo

    Mwana Lugogo, Chief Ethics & Compliance Officer

  • Takako Ohyabu

    Takako Ohyabu, Chief Global Corporate Affairs & Sustainability Officer

Operating MetricsView all

Phase III Trials Products (Oncology)

6

Jul, 2023

Phase III Trials Products (PDT)

5

Jul, 2023

Filed Trials Products (Gastro-Enterology)

3
25.0%

Jul, 2023

LocationsView all

85 locations detected

  • Tokyo, Tokyo HQ

    Japan

    1-1, Nihonbashi-Honcho 2-chome, Chuo-ku

  • Cambridge, MA

    United States

    650 E Kendall St

  • Cambridge, MA

    United States

    75 Sidney St

  • Lexington, MA

    United States

    95 Hayden Ave

  • San Diego, CA

    United States

    9625 Towne Centre Dr

  • Buenos Aires, CABA

    Argentina

    Av. del Libertador 7208 Piso 14

and 79 others

Takeda Financials

Summary Financials

Revenue (Q3, 2024)
¥1.1T
Gross profit (Q3, 2024)
¥919.7B
Net income (Q3, 2024)
¥105.8B
Cash (Q3, 2024)
¥288.4B
EBIT (Q3, 2024)
¥106.0B
Enterprise value
$10.8T

Footer menu